Side-by-side financials for CUE and AZN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | CUE | AZN |
|---|---|---|
| Market cap | - | $286.27 B |
| US-listed rank | - | #49 |
| Revenue (latest FY) | $27.47M | - |
| Net income (latest FY) | -$26.60M | - |
| Net margin | -96.9% | - |
| SEC filings | 496 | 1,004 |
Full pages: Cue Biopharma, Inc. and AstraZeneca PLC, or browse the full rankings.